A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesterase.

bisnorcymserine (ANVS-301) - Annovis Bio

http://www.ncbi.nlm.nih.gov/pubmed/42127455

Apostolos Manolopoulos; David Tweedie; Dimitrios Kapogiannis; Iason Tzieras; Josephine M Egan; Maria Maccecchini; Nigel H Greig; Weiming Luo

May 18, 2026